menu
    • menu
    [{"orgOrder":0,"company":"Syndeio Biosciences","sponsor":"Catalio Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Financing","leadProduct":"Zelquistinel","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Syndeio Biosciences","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.089999999999999997,"dosageForm":"Oral Tablet","sponsorNew":"Syndeio Biosciences \/ Catalio Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Syndeio Biosciences \/ Catalio Capital Management"}]

    Find Clinical Drug Pipeline Developments & Deals by Syndeio Biosciences

    Menu

    Syndeio Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Syndeio Biosciences

                            U.S.A arrow
                            Pharmex
                            Not Confirmed

                            Syndeio Biosciences

                            U.S.A arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zelquistinel

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Catalio Capital Management

                            Deal Size : $90.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Syndeio Biosciences Launches to Pioneer Synapse-Targeted Neurotherapeutics

                            Details : The net procceds will be used for Syndeio’s lead candidate, GATE-251 aka zelquistinel, an orally bioavailable positive allosteric modulator of the NMDA receptor, to treat major depressive disorder.

                            Product Name : GATE-251

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            May 27, 2025

                            Lead Product(s) : Zelquistinel

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Catalio Capital Management

                            Deal Size : $90.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth